Technical Analysis for ATNX - Athenex, Inc.

Grade Last Price % Change Price Change
grade F 11.62 1.31% 0.15
ATNX closed up 1.77 percent on Tuesday, January 15, 2019, on 37 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ATNX trend table...

Date Alert Name Type % Chg
Jan 15 Narrow Range Bar Range Contraction 1.31%
Jan 15 NR7 Range Contraction 1.31%
Jan 15 Stochastic Reached Oversold Weakness 1.31%
Jan 15 Oversold Stochastic Weakness 1.31%
Jan 14 Down 3 Days in a Row Weakness 3.11%
Jan 10 Fell Below 20 DMA Bearish -2.43%
Jan 10 Fell Below 50 DMA Bearish -2.43%
Jan 10 MACD Bearish Centerline Cross Bearish -2.43%
Jan 10 MACD Bearish Signal Line Cross Bearish -2.43%
Jan 10 Inside Day Range Contraction -2.43%

Older signals for ATNX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:
Profile
Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.
Is ATNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jan 12 Stocks To Watch: Action From Detroit And ICR
Jan 10 Athenex Completes Enrollment Target for Breast Cancer Study
Jan 10 Buffalo startups surpassed $200 million in VC and angel funding in 2018
Jan 9 Athenex completes enrollment in Oraxol Phase 3 study
Jan 9 Athenex Announces Completion of Target Enrollment in the Oraxol Phase III Study
Jan 4 Teresa Bair talks about the big year ahead for Athenex
Jan 3 Chongqing Jingdong Pharmaceutical and Athenex Announce a Strategic Partnership and Licensing Agreement to Develop and Commercialize KX2-391 in China
Dec 26 Athenex launches Levothyroxine Sodium for Injection
Dec 26 Athenex Pharmaceutical Division, an Athenex, Inc. Company, Launches Levothyroxine Sodium for Injection
Dec 20 What Kind Of Shareholders Own Athenex, Inc. (NASDAQ:ATNX)?
See more ATNX news...
Indicators
Indicator Value
52 Week High 20.9
52 Week Low 9.83
Average Volume 395,737
200-Day Moving Average 15.6335
50-Day Moving Average 12.2151
20-Day Moving Average 12.115
10-Day Moving Average 12.076
Average True Range 0.728
ADX 12.09
+DI 14.9346
-DI 21.4633
Chandelier Exit (Long, 3 ATRs ) 11.396
Chandelier Exit (Short, 3 ATRs ) 12.864
Upper Bollinger Band 13.5179
Lower Bollinger Band 10.7121
Percent B (%b) 0.27
BandWidth 23.159719
MACD Line -0.1861
MACD Signal Line -0.0788
MACD Histogram -0.1073
Fundamentals Value
Market Cap 654.52 Million
Num Shares 57.1 Million
EPS -3.47
Price-to-Earnings (P/E) Ratio -3.31
Price-to-Sales 47.88
Price-to-Book 7.97
PEG Ratio 0.98
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.92
Resistance 3 (R3) 11.88 11.69 11.85
Resistance 2 (R2) 11.69 11.58 11.71 11.82
Resistance 1 (R1) 11.58 11.50 11.64 11.62 11.79
Pivot Point 11.39 11.39 11.42 11.41 11.39
Support 1 (S1) 11.28 11.28 11.34 11.32 11.15
Support 2 (S2) 11.09 11.20 11.11 11.12
Support 3 (S3) 10.98 11.09 11.10
Support 4 (S4) 11.02